Weiss Ratings Reaffirms Sell (D-) Rating for Janux Therapeutics (NASDAQ:JANX)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for Janux Therapeutics (NASDAQ: JANX), indicating ongoing concerns regarding the company's stock performance.
• Analysts have issued mixed ratings for Janux Therapeutics, with two rating it as a Strong Buy and others giving it ratings ranging from "Buy" to "Hold," highlighting inconsistencies in market perception.
• The company's stock is currently trading at $24.20, significantly below its 52-week high of $71.71, with a projected average target price of $78.31 according to analyst estimates.

Janux Therapeutics (NASDAQ:JANX - Get Free Report)'s stock had its "sell (d-)" rating reissued by analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Several other analysts have also recently weighed in on the stock. Raymond James Financial initiated coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They issued an "outperform" rating and a $65.00 price objective for the company. Barclays started coverage on shares of Janux Therapeutics in a report on Wednesday, September 17th. They issued an "overweight" rating and a $47.00 target price on the stock. Stifel Nicolaus reissued a "buy" rating and issued a $45.00 target price on shares of Janux Therapeutics in a report on Wednesday, September 10th. Truist Financial started coverage on shares of Janux Therapeutics in a report on Wednesday, September 10th. They issued a "buy" rating and a $100.00 target price on the stock. Finally, Piper Sandler started coverage on shares of Janux Therapeutics in a report on Monday, August 18th. They issued an "overweight" rating and a $42.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $78.31.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $24.20 on Wednesday. The firm has a 50-day moving average of $23.75 and a 200-day moving average of $25.43. The stock has a market cap of $1.45 billion, a PE ratio of -13.44 and a beta of 2.82. Janux Therapeutics has a 52-week low of $21.73 and a 52-week high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.07). As a group, analysts predict that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC grew its holdings in Janux Therapeutics by 1,574.0% during the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock worth $45,000 after acquiring an additional 1,574 shares during the last quarter. US Bancorp DE lifted its position in shares of Janux Therapeutics by 2,402.9% in the 1st quarter. US Bancorp DE now owns 1,727 shares of the company's stock worth $47,000 after purchasing an additional 1,658 shares during the period. KBC Group NV acquired a new position in shares of Janux Therapeutics in the 1st quarter worth approximately $66,000. FNY Investment Advisers LLC lifted its position in shares of Janux Therapeutics by 6,928.6% in the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock worth $66,000 after purchasing an additional 2,425 shares during the period. Finally, Osaic Holdings Inc. lifted its position in shares of Janux Therapeutics by 704.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company's stock worth $80,000 after purchasing an additional 3,037 shares during the period. 75.39% of the stock is owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.